Pure Global AI
NCT06361212Completed

Ethoximod Pharmacokinetics In Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Ethoximod in Healthy Subjects.
Longevity Inc.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Psoriasis
Drug/Device/Intervention
Ethoximod
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Longevity Inc.
Location
Changchun, China
Timeline & enrollment
Phase
Phase 1
Start date
Sep 01, 2022
End date
Jan 12, 2024
Enrollment
65 participants
Primary outcome

Peak plasma concentration (Cmax),Time to peak plasma concentration (Tmax),The lowest plasma concentration (Cmin),Half-life (t1/2),Number of adverse events and number of participants with adverse events

Summary

The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and
 pharmacodynamics of Ethoximod in healthy subjects. The main questions it arms to answer are:
 
 1. to evaluate the safety and tolerance of Ethoximod in healthy subjects after single or
 repeated doses.
 
 2. to assess the pharmacokinetics and pharmacodynamics of Ethoximod in healthy subjects
 after single or repeated doses.
 
 3. to evaluate of the effect of food on the pharmacokinetics of Ethoximod in healthy
 subjects Participants will receive test tablets or placebo at the indicated date and
 collect blood samples.

ICD-10 classifications
PsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasisPsoriasis vulgaris
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06361212
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06361212 through Pure Global AI's free database. This Phase 1 trial is sponsored by Longevity Inc. and is currently Completed. The study focuses on Psoriasis. Target enrollment is 65 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.